top of page
Hope4ATRT_Logo_small.png

ATRT Investigators -

Washington

Sarah Leary, MD

Seattle Children’s Hospital [Seattle, WA]

Sarah Leary, MD, is an attending physician in the Cancer and Blood Disorders Center at Seattle Children's Hospital and Associate Professor of Pediatrics at the University of Washington School of Medicine. Her clinical and research focus is in the area of pediatric brain tumors.


Locally, she serves on the Tumor Tissue Subcommittee and the Research Review Committee; Nationally, she is leading several clinical trials to study new medications for children with brain tumors at Seattle Children's Hospital, through the Children's Oncology Group, the Pacific Pediatric Neuro-Oncology Consortium (PNOC)and the Pediatric Brain Tumor Consortium (PBTC). Dr. Leary works with laboratory investigators at the Fred Hutchinson Cancer Research Center and the Seattle Children's Research Institute as well as the Pathology Department at Seattle Children's Hospital to identify novel therapeutic targets and tests. The goal of her clinical and translational research is to improve outcomes for brain tumor patients by developing biologically targeted therapeutics.


Investigator of Clinical Trials:  



.

Nicholas Vitanza, MD

Seattle Children’s Hospital [Seattle, WA]

Dr. Nick Vitanza is an Associate Professor at the University of Washington and a pediatric neuro-oncologist at Seattle Children’s, where he directs the Vitanza Lab in the Ben Town Center for Childhood Cancer Research. He also serves as Seattle Children's CNS CAR T cell Lead and DIPG Research Lead. Dr. Vitanza completed his pediatric oncology fellowship at NYU before a neuro-oncology fellowship at Stanford where his work on combinatorial targeted therapy for DIPG was published in Science Translational Medicine and Cancer Cell. In 2016, he joined Seattle Children’s where he oversees 3 CNS CAR T cell trials that have delivered over 300 intracranial CAR T cell doses to children with recurrent CNS tumors and DIPG - with preliminary findings published in Nature Medicine. Through his collaborative laboratory and clinical research programs, Dr. Vitanza aims to optimize epigenetic and immunotherapeutic targeting of pediatric CNS tumors with a goal to rapidly translate findings to the clinic and improve the lives of affected children.


VISIT SEATTLE CHILDREN'S CNS CAR T PAGE FOR MORE RESEARCH AND CLINICAL TRIALS


Nicholas A. Vitanza, MD

Assistant Professor & Pediatric Neuro-Oncologist, Seattle Children’s Hospital

CNS CAR T Cell Lead, Seattle Children’s Research Institute

Affiliate Investigator, Fred Hutchinson Cancer Research Center


CNS CAR T-cell trial Lead: 

.

bottom of page